Immuno Aktiengesellschaft Fur Chemisch-medizinische Produkte

Immuno Aktiengesellschaft

Baxter Aktiengesellschaft

Immuno Aktiengesellschaft Fur Chemisch-medizinisch Produkte

Yendra Linnau

Johann J Eibl

Otto Schwarz

Anton Philapitsch

Hans Peter Schwarz

Thomas Seelich

Ernst Hetzl

Franz Loblich

Fritz Elsinger

Gunther Wober

Friedrich Elsinger

Friedrich Dorner

Wolfgang Teschner

Karl Trambauer

Wolfgang Frechinger

Maria Sazgary

Peter Turecek

Hans-Peter Schwarz

Alfred Weber

Noel Barrett

Gunter Wober

Martha Eibl

Ewald Molinari

Wolfgang Sch&ouml;nhofer

Susanne Pfeiler

Sonja Svatos

Herbert Gritsch

Heinz Leibl

Wolfgang Schoenhofer

Hermann Wolf

H Peter Matthiessen

Adolf Lindner

Silvia Neppl

Herwig Igel

Gerhard Pölsler

There is disclosed a method of preparing a plasma-protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps:

Process for producing a plasma protein-containing medicament with reduced concentration of citrate and metals

The invention relates to a method for the production of factor VIII:C/von Willebrand factor complex from plasma or a plasma fraction by chromatography in a cation exchanger, wherein the factor VIII:C/von Willebrand factor complex is obtained with at least 300 times the purity of the plasma and the yield of factor VIII:C and the von Willebrand factor is at least 50% in relation to cryoprecipitates or analogous plasma fractions.

Method for producing a factor VIII/von Willebrand factor complex

A method of purifying antithrombin III (AT III) from a starting material containing an AT III/heparin complex or an AT III/heparinoid complex is disclosed. First, the method comprises adsorbing the AT III/heparin complex or the AT III/heparinoid complex on an anion exchanger material. Second, the method involves separating the AT III from the adsorbed AT III/heparin complex or an AT III/heparinoid complex by elution with a buffer having a pH ranging from 8.5 to 10.5 and a conductivity between 10 and 60 mS.

Method for purification of antithrombin III using an anion exchanger

There is disclosed a highly purified complex comprising the components factor VIII and vWF having a specific activity of at least 70, preferably 100 to 300 U factor VIII:C/mg, a stable pharmaceutical preparation containing this complex as well as a method of producing the same.

Highly purified factor VIII complex

A blood product, exclusive of albumin, inactivated relative to infectious agents, the blood product conforming to a total virus reduction factor of at least 40, having a biological acitity of at least 50%, based on its activity prior to effecting inactivation of the infectious agents, the blood product being producible from conventional blood products and being virus-safe.

Blood product, a method of producing the same and a method of

Inflammation can be treated or prevented altogether by administering a preparation comprising IgA. These preparations also can effect immunomodulation. Preferably, the preparation includes multimeric IgA and is essentially free of IgG in its various forms. Other compounds, such as antibiotics, antiphlogistic agents and antacids, also may be administered. Immunoglobulin A may also be used in vaccines to prevent inflammation. Additionally, an improved assay for evaluating anti-inflammatory activity is provided.

Composition and method for preventing and treating inflammation with

A thrombin of human or animal origin is free of infectious agents and is produced by activation of prothrombin subjected to a heat treatment for the inactivation of infectious agents.

Thrombin and method of producing the same

This invention is directed to a method of evaluating viral reduction capability of a viral inactivation step in a viral inactivation procedure. The method requires spiking a biological product with a virus more than once during the viral inactivation step so that a virus reduction factor can be calculated.

Method of determining the virus inactivation capacity of an inactivation

A stable, highly concentrated intravenously tolerable immunoglobulin preparation is described having an immunoglobulin content from 13.5 to 17.5% (w/v), an osmolarity from 250 to 600 mOs/l and a viscosity of no more than 9 cP. The immunoglobulin preparation possesses an exceptional imperishability and also is used as a highly concentrated preparation without problems due to its low viscosity.

Highly concentrated immunoglobulin preparation and method for its

A thrombolytic, parenterally administrable drug containing activated protein C is provided for. The drug is free of serum amyloid P, thrombin activity, infectious agents and antibodies against protein C and activated protein C.

Parenterally administrable drug having thrombolytic activity and

A process for preparing lys-plasminogen from blood plasma or blood plasma products having a specific activity of at least 17.5 caseinolytic units/mg protein and at lease 50 .mu.moles/g protein nitrogen as well as a an electrophoretic purity of at least 90% is presented. Cohn fraction III is obtained by phosphate precipitation from blood plasma or blood plasma products. A crude plasminogen fraction is then obtained by precipitating most non-plasminogen proteins with ethanol. The crude plasminogen is absorbed on immobilized lysine affinity column. Elution followed by precipitation obtains a purified plasminogen. The purified plasminogen is converted to lys-plasminogen with plasmin having an activity from 0.01 to 0.1 .mu.moles/ml min relative to chromogenic substrate H-D-Val-L-Leu-L-Lys-p-nitroanilide by dialyzing at a temperature of about 1.degree. to 20.degree. C. for a time period of about 6 to 60 hours. The conversion is interrupted by adding aprotinin. The resulting lys-plasminogen is lyophilized to produce a lyophilized lys-plasminogen.

Method of producing LYS-plasminogen

A method of dissolving venous thrombi using a thrombolytic, parenterally administrable drug containing activated protein C is described. The drug can be free of serum amyloid P, thrombin activity, infectious agents and antibodies against protein C and activated protein C.

Method of dissolving venous Thrombi using drug containing activated

Factor IX is selectively adsorbed by means of hydrophobic chromatography from an aqueous mixture containing at least one plasma zymogen or a vitamin-K dependent protein in addition to factor IX. By this method, the efficient enrichment of factor IX for the production of pharmaceutical preparations has become possible.

Complex containing coagulation factor IX

The invention relates to a method of producing virus-safe highly purified factor VIII. The method includes a combination of the following measures:

Method of producing a factor VIII preparation

There is disclosed a method of activating prothrombin by means of trypsin, wherein the prothrombin is recovered from a blood or plasma fraction, treated with trypsin immobilized on a water-insoluble carrier, and separated from the immobilized trypsin after activation.

Growing community of inventors

Vienna, Austria

Yendra Linnau